Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 6/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731960 | 0.90 | PLK1 (0.48) | CNR2CNR1KDM6BKDM4CPLK1 | |
| SCHEMBL13783620 | 0.89 | KDM6B (0.53) | KDM6BKDM4CPLK1CA12CA9 | |
| SCHEMBL23748664 | 0.88 | CNR2 (0.50) | CNR2CNR1KDM6BKDM4CPLK1 | |
| SCHEMBL5136114 | 0.87 | PLK1 (0.51) | CNR2CNR1KDM6BKDM4CPLK1 | |
| SCHEMBL2382719 | 0.86 | TSHR (0.46) | CNR2CNR1PLK1ALDH1A1HSD17B10 | |
| SCHEMBL466141 | 0.86 | PLK1 (0.63) | CNR2CNR1KDM6BKDM4CPLK1 | |
| SCHEMBL7603848 | 0.85 | CNR2 (0.50) | CNR2CNR1KDM6BKDM4CPLK1 | |
| SCHEMBL26976849 | 0.85 | KDM4E (0.49) | KDM6BKDM4CPLK1HPGDALDH1A1 | |
| SCHEMBL28310186 | 0.85 | CNR2 (0.50) | CNR2CNR1KDM6BKDM4CPLK1 | |
| SCHEMBL11430175 | 0.84 | PLK1 (0.66) | CNR2CNR1KDM6BKDM4CPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8012635-A | — | — | None | — | — | JP | disclosed |
| EP-3239133-B1 | DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF | CONSEJO SUPERIOR INVESTIGACION (ES) | 2020-04-01 | — | — | EP | disclosed |
| US-20180037538-A1 | DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2018-02-08 | — | — | US | disclosed |
| EP-3239133-A1 | DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2017-11-01 | — | — | EP | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7091353-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| JP-H0812635-A | PRODUCTION OF ACYLAMINOPHTHALIC ACID DERIVATIVE | SUMITOMO CHEM CO LTD | 1996-01-16 | — | — | JP | disclosed |
| US-4088651-A | Acylamino quinophthalone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1978-05-09 | — | — | US | disclosed |
| US-4088651-A | Acylamino quinophthalone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CNR2 1170/4885CNR1 1808/4885KDM6B 4777/4885 |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | TNF, IKZF3, TNFRSF1A | CNR2 1163/4885CNR1 1731/4885KDM6B 4803/4885 |
| US-20180037538-A1 | DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF | NCS1, CACNA1B, ORAI1 | CNR2 66/4885CNR1 80/4885KDM6B 1306/4885 |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, TNFRSF1A | CNR2 1163/4885CNR1 1731/4885KDM6B 4803/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CNR2 1170/4885CNR1 1808/4885KDM6B 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.